Equity analyst consensus ratings for SOPHiA GENETICS (NASDAQ: SOPH) generally reflect a mix of holds and moderate buys, driven by its recurring SaaS revenue model and expansion in clinical genomic testing partnerships, though it remains a small-cap growth stock working toward sustained profitability. What are your primary financial return targets and risk parameters? Professional financial guidance is recommended before making any investment decisions.